caa a22 4500 445332220 CHVBK 20180317142741.0 cr unu---uuuuu 170323e20110601xx s 000 0 eng 10.1007/s10198-010-0223-9 doi (NATIONALLICENCE)springer-10.1007/s10198-010-0223-9 Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy [Elektronische Daten] [Eberhard Wille, Jürgen Scholze, Eduardo Alegria, Claudio Ferri, Sue Langham, Warren Stevens, David Jeffries, Kerstin Uhl-Hochgraeber] The presence of metabolic syndrome in patients with hypertension significantly increases the risk of cardiovascular disease, type 2 diabetes and mortality. Our aim is to estimate the economic burden to the health service of metabolic syndrome (MetS) in patients with hypertension and its consequences, in three European countries in 2008, and to forecast future economic burden in 2020 using projected demographic estimates and assumptions around the growth of MetS. An age-, sex- and risk group-structured prevalence-based cost of illness model was developed using the United States Adult Treatment Panel III of the National Cholesterol Education Program criteria to define MetS. Data sources included published information and public use databases on disease prevalence, incidence of cardiovascular events, prevalence of type 2 diabetes, treatment patterns and cost of management in Germany, Spain and Italy. The economic burden to the health service of MetS in patients with hypertension has been estimated at 24,427 €, 1,900 € and 4,877 € million in Germany, Spain and Italy, and is forecast to rise by 59, 179 and 157%, respectively, by 2020. The largest components of costs included the management of prevalent type 2 diabetes and incident cardiovascular events. Mean annual costs per hypertensive patient were around three-fold higher in subjects with MetS compared to those without and rose incrementally with the additional number of MetS components present. In conclusion, the presence of MetS in patients with hypertension significantly inflates economic burden, and costs are likely to increase in the future due to an aging population and an increase in the prevalence of components of MetS. Springer-Verlag, 2010 Cost of illness nationallicence Health care costs nationallicence Prevalence nationallicence Metabolic syndrome nationallicence Hypertension nationallicence Wille Eberhard Fakultät für Volkswirtschaftslehre, L 7, 3-5, 2. OG, Raum 21, 68131, Mannheim, Germany aut Scholze Jürgen Department of Medicine, Outpatient Clinic, CCM, Charite-Universitatsmedizin Berlin, Luisenstrasse 11-13, 10117, Berlin, Germany aut Alegria Eduardo Servicio de Cardiología, Policlínica Gipuzkoa, San Sebastián, Spain aut Ferri Claudio Division of Internal Medicine, Hypertension and Cardiovascular Prevention Center, Department of Internal Medicine and Public Health, San Salvatore Hospital, University of L'Aquila, L'Aquila, Italy aut Langham Sue Independent Health Economist, Manchester, UK aut Stevens Warren Independent Health Economist, Boston, USA aut Jeffries David Statistics and Data Management, MRC Tropical Disease Research Unit, Banjul, Gambia aut Uhl-Hochgraeber Kerstin Global Health Economics and Outcomes Research, Bayer Schering Pharma AG, Berlin, Germany aut The European Journal of Health Economics Springer-Verlag 12/3(2011-06-01), 205-218 1618-7598 12:3<205 2011 12 10198 https://doi.org/10.1007/s10198-010-0223-9 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10198-010-0223-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Wille Eberhard Fakultät für Volkswirtschaftslehre, L 7, 3-5, 2. OG, Raum 21, 68131, Mannheim, Germany aut NATIONALLICENCE 700 1- Scholze Jürgen Department of Medicine, Outpatient Clinic, CCM, Charite-Universitatsmedizin Berlin, Luisenstrasse 11-13, 10117, Berlin, Germany aut NATIONALLICENCE 700 1- Alegria Eduardo Servicio de Cardiología, Policlínica Gipuzkoa, San Sebastián, Spain aut NATIONALLICENCE 700 1- Ferri Claudio Division of Internal Medicine, Hypertension and Cardiovascular Prevention Center, Department of Internal Medicine and Public Health, San Salvatore Hospital, University of L'Aquila, L'Aquila, Italy aut NATIONALLICENCE 700 1- Langham Sue Independent Health Economist, Manchester, UK aut NATIONALLICENCE 700 1- Stevens Warren Independent Health Economist, Boston, USA aut NATIONALLICENCE 700 1- Jeffries David Statistics and Data Management, MRC Tropical Disease Research Unit, Banjul, Gambia aut NATIONALLICENCE 700 1- Uhl-Hochgraeber Kerstin Global Health Economics and Outcomes Research, Bayer Schering Pharma AG, Berlin, Germany aut NATIONALLICENCE 773 0- The European Journal of Health Economics Springer-Verlag 12/3(2011-06-01), 205-218 1618-7598 12:3<205 2011 12 10198 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer